To position these data with respect to current clinical approaches for BRAF-mutant melanoma, and in line with earlier in vitro experiments, we next compared the impact of administration of AZD8186 or targeted deletion of PREX2 (via CRISPR/Cas9) upon efficacy of the cobimetinib/dabrafenib doublet MAPK-targeting regimen. The gene discussed is BRAF; the disease is melanoma.